Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
Triple-Negative Breast Cancer
Advertisement
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Researchers aimed to evaluate the roll of ERCC1 expression in predicting response to adjuvant chemotherapy for TNBC.
A novel method can assess which patients with TNBC could benefit from immunotherapy.
New research shows that selenium, a mineral commonly found in Brazil nuts, could hold the key to stopping the spread of TNBC.
Cancer researchers at Brigham and Women’s Hospital have identified a potential new method for the treatment of TNBC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.